Member Info for neilrich3

"All vaccines are failing to provide ongoing protection it appears, not sure what will happen once a new variant to Delta comes along. "

You make a good point...the answer: We shall be more dependent upon testing than ever before!

Nobody is fully vaccinated for long, it is known that the efficacy of the Vaccine shall continue to wane, unfortunately a never ending circle of testing and vaccination.

Please expand upon why you think testing is over?

Former college and friend who works as a manager at a testing site has just had his contract renewed to January 2023.

Labortechnik?
https://www.youtube.com/watch?v=1WRMEBI7p5Q

Alleged falsified data used in the Pfizer trial in the race to be first with a vaccine....surly not!! Wonder how much money DHSC have paid Pfizer.

https://www.youtube.com/watch?v=THv33zWykJc

The issue is that you hear people say that we shall have to learn to live with the virus, however living with the virus does not mean ignoring it and going back to what was perceived normal. Living with the virus mean regular testing, vaccination and precautions such as mask wearing in certain situations.

Yes, has been posted many times. DA comes across very well in my opinion, only a matter of time before he's doing the same for NCYT.

Possibly, although obviously you’d have to test the patient before prescribing a course of antiviral . Former colleague of mine made redundant due to the pandemic, but very quickly found a job as a manager at a COVID testing site, reports that he has been offered a new contract 40 hours a week through to Jan 2023.

Not necessarily, check the financials for Amryt, revenue has increased from £1.35m in 2016 to $182.61m in 2020. The forecast revenue for 2021 and 2022 is £160m and £253m.

This happened under David as Chief Commercial Officer and latterly as Chief Business Officer.

Do not write David off, give the guy a chance, clearly he has talent, before long we shall be watching him on TV, the likes of Bloomberg and CNBC, but not after just 3 weeks in the job, like some on here appear to have been expecting.

This is also evident in headcount which has increased from 110 at the start of 2020 to in excess of 275 at the end of June 2021, driving up costs year-on-year.

Wilson, EXMEX the full year report had the headcount at 275. I don't dispute that, not all employees choose to have a profile upon Linkedin, it is a networking site. What I'm saying is that Linkedin is a good Barometer, the number of employees continue to increase from 130 in the Summer to 154 Today, therefore should we extrapolate, I'd imagine that the actual headcount is now North of 300.

154 from the data available upon LinkedIn, beginning of the week it was 151 and a couple of months back it was 130. Obviously LinkedIn does not include all employees, however I feel that it is a good barometer, Novacyt continue to expand the workforce. Unfortunately still only two listed as USA based and one in Chile.

Appreciate that DA is attracting much criticism for his silence, however hopefully it shall be worth the wait, everyone here and the markets blown away when he speaks for the first time, I'd expect to hear him speak upon the likes of Bloomberg before the end of the year. Something has to be brewing behind the scenes, troubled companies don't continue to recruit at this level, don't forget that no news is good news.

Exactly....storm in a tea cup!! Also, worth remembering the claims made by the likes of Pfizer when they released the vaccine and how wrong the markets were then, unfortunately COVID ain't going anywhere, one day the markets shall wake up to that fact.

As reported below, it shall be challenging treat patients early enough. We already know that LFT is not the best when it comes to early detection, PCR shall be essential going forward.

Andrew Hill, a senior visiting research fellow in pharmacology at the University of Liverpool, called it a “very important” result.
“We need treatments for people with mild infections to prevent hospitalisation and lower the burden on overwhelmed health services,” he said. But he added that it could be challenging to treat patients early enough, within the first five days.

Fortunately the Pfizer drug before being prescribed to those categorised as vulnerable shall require a positive PCR test. Also, the Pfizer drug does not stop transmission of the virus. Hardly a game changer.

This past week the Novacyt headcount upon Linkedin has increased again from 151 to 154.

Where does it state that Primerdesign supplied 14m tests, I can see the piece of pie in the pie chart, however the colours on the corresponding key with listed companies are poorly depicted making it very difficult to match up against the chart.

Based upon the 2020 accounts and the £100m guidance from the company for this year, I feel that this 14m test supplied claim is incorrect, unfortunately.

End of the day, potential Co-prep customers are not monitoring our RNS, you don't market new products via RNS. I feel that some are becoming fixated about the lack of RNS.

Interesting that the Q machines as shown within the Novacyt image released upon Twitter are branded at the Mygo Pro and Mygo Mini, I thought that this model name had been dropped following the acquisition of IT IS, but obviously not.

Would be interesting to know the price tag upon the Co-Prep, I'm think around £3-4k.